3,411 Shares in Repligen Corporation $RGEN Bought by Whalen Wealth Management Inc.

Whalen Wealth Management Inc. bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 3,411 shares of the biotechnology company’s stock, valued at approximately $456,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. Price T Rowe Associates Inc. MD raised its stake in shares of Repligen by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock valued at $962,711,000 after buying an additional 430,039 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Repligen by 1.3% during the first quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company’s stock worth $130,317,000 after acquiring an additional 13,284 shares during the period. Brown Capital Management LLC raised its position in Repligen by 16.3% during the second quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company’s stock valued at $125,036,000 after acquiring an additional 141,241 shares in the last quarter. Northern Trust Corp lifted its holdings in Repligen by 1.0% in the first quarter. Northern Trust Corp now owns 498,447 shares of the biotechnology company’s stock valued at $63,422,000 after acquiring an additional 4,734 shares during the period. Finally, Geneva Capital Management LLC boosted its position in Repligen by 239.6% in the 2nd quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock worth $60,639,000 after purchasing an additional 343,991 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on RGEN. Wall Street Zen lowered shares of Repligen from a “buy” rating to a “hold” rating in a report on Tuesday, November 4th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Tuesday, September 2nd. Barclays increased their target price on shares of Repligen from $175.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday. Evercore ISI upped their price target on Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Finally, Wells Fargo & Company raised their price objective on Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $177.92.

Insiders Place Their Bets

In other Repligen news, COO James Bylund sold 2,191 shares of the business’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total value of $331,301.11. Following the transaction, the chief operating officer directly owned 21,520 shares in the company, valued at $3,254,039.20. The trade was a 9.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Karen A. Dawes sold 275 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the sale, the director owned 91,821 shares of the company’s stock, valued at $14,783,181. This represents a 0.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 49,657 shares of company stock valued at $7,721,077 over the last ninety days. Company insiders own 1.20% of the company’s stock.

Repligen Stock Performance

Shares of Repligen stock opened at $157.72 on Friday. The business’s 50 day moving average price is $156.75 and its 200 day moving average price is $135.54. The company has a market cap of $8.88 billion, a price-to-earnings ratio of 7,889.94, a PEG ratio of 3.53 and a beta of 1.11. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. The business had revenue of $188.81 million during the quarter, compared to the consensus estimate of $181.23 million. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The company’s revenue for the quarter was up 21.9% on a year-over-year basis. During the same period last year, the company earned $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, research analysts predict that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.